SCHEDULE: TSSP Sub-Fund HoldCo and Alan Waxman Disclose Significant Stake in Caris Life Sciences
Beneficial Ownership Disclosure
TSSP Sub-Fund HoldCo, LLC and Alan Waxman have jointly disclosed beneficial ownership of 8.3% and 8.8% respectively, of Caris Life Sciences, Inc.'s Common Stock as of June 30, 2025.
Summary
- TSSP Sub-Fund HoldCo, LLC and Alan Waxman have jointly filed a Schedule 13G, disclosing their beneficial ownership in Caris Life Sciences, Inc.
- As of June 30, 2025, TSSP Sub-Fund HoldCo, LLC beneficially owns 23,166,128 shares of Common Stock, representing 8.3% of the class.
- As of June 30, 2025, Alan Waxman beneficially owns 24,385,399 shares of Common Stock, representing 8.8% of the class.
- The calculation of ownership percentages is based on 277,932,779 shares of Common Stock outstanding as of June 30, 2025, as disclosed in the Issuer's Form 424B4 filed on June 20, 2025.
- Both reporting persons disclaim beneficial ownership of shares held directly by Barnett Equity Holdings, LLC, Sixth Street Specialty Lending Inc., TOP III Barnett Investments, LLC, Barnett Equity Holdings II, LLC, and TAO Barnett Investments, LLC, despite their indirect relationships.
Sentiment
Score: 5
Explanation: This filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional and individual investor stake in Caris Life Sciences, a company operating in the precision medicine and oncology space. Such disclosures highlight investor confidence or strategic positioning within the competitive healthcare and biotechnology sectors.
Stakeholder Impact
- Increased transparency regarding significant ownership stakes provides shareholders with a clearer picture of the company's investor base.
Key Dates
| Date | Description |
|---|---|
| December 31, 2024 | Date of Authorization and Designation Letter by Alan Waxman for Joshua Peck to sign on his behalf. |
| June 20, 2025 | Issuer's Prospectus filed on Form 424B4, disclosing shares outstanding. |
| June 30, 2025 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| July 28, 2025 | Signature date of the Schedule 13G filing. |
Keywords
Caris Life Sciences, TSSP Sub-Fund HoldCo, Alan Waxman, Schedule 13G, beneficial ownership, common stock, investment, healthcare, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.